← Leaderboards
Hyunsuk Shim
Emory University
$7,356,562
Attributed
$15,516,876
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,516,876 · 13
By mechanism
U01$7,980,174 · 3
R01$3,749,583 · 3
R21$1,983,508 · 4
P50$900,453 · 1
RC1$850,335 · 1
P20$52,823 · 1
Top collaborators
- Hui-Kuo Shu11 shared
- Lee Cooper8 shared
- Xiaoping P Hu7 shared
- Jeffrey J Olson7 shared
- Peter B Barker5 shared
- Andrew A. Maudsley5 shared
- Eric Albert Mellon4 shared
- Hui Han3 shared
Most similar at Emory University
Same institution · by research overlap
- Lee Cooper$6,337,159
- Hui-Kuo Shu$1,642,136
- Xiao-Jiang Li$16,112,155
- Jeffrey J Olson$1,258,074
- Adam I Marcus$15,360,223
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorBaseMapsSiteCellsDoseOperative Surgical ProceduresPharmaceutical PreparationsImageTissuesPlaySignal TransductionClinicInhibitor/AntagonistRecurrenceProgramsTechnologyDesignPre-ClinicalGlioblastomaToxic EffectNewly DiagnosedSmall MoleculeSpecificity
Grant awards (39)
Improved whole-brain spectroscopic MRI for radiation therapy planning$621,676
U01 · FY2025 · CA · contact PI
Improved whole-brain spectroscopic MRI for radiation therapy planning$551,573
U01 · FY2024 · CA · contact PI
Improved whole-brain spectroscopic MRI for radiation therapy planning$601,791
U01 · FY2023 · CA · contact PI
Improved whole-brain spectroscopic MRI for radiation therapy planning$661,161
U01 · FY2022 · CA · contact PI
Improved Whole-Brain Spectroscopic MRI for Radiation Treatment Planning$775,037
U01 · FY2020 · EB · contact PI
Improved Whole-Brain Spectroscopic MRI for Radiation Treatment Planning$784,397
U01 · FY2019 · EB · contact PI
Spectroscopic MRI to guide radiation dose escalation for glioblastoma patients$138,906
R01 · FY2019 · CA · contact PI
Improved Whole-Brain Spectroscopic MRI for Radiation Treatment Planning$813,062
U01 · FY2018 · EB · contact PI
Spectroscopic MRI to guide radiation dose escalation for glioblastoma patients$287,297
R01 · FY2018 · CA · contact PI
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$617,130
U01 · FY2017 · CA · contact PI
Spectroscopic MRI to guide radiation dose escalation for glioblastoma patients$312,894
R01 · FY2017 · CA · contact PI
Development of automated web-based spectroscopic MRI clinical interface$233,258
R21 · FY2017 · NS · contact PI
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$623,858
U01 · FY2016 · CA · contact PI
Development of anti-CXCR4 compounds to block breast cancer metastasis$320,735
R01 · FY2016 · CA · contact PI
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$632,744
U01 · FY2015 · CA · contact PI
Development of anti-CXCR4 compounds to block breast cancer metastasis$326,209
R01 · FY2015 · CA · contact PI
Improving extent of glioblastoma resection by combining volumetric MRSI and 5-ALA$322,932
R21 · FY2015 · CA · contact PI
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$626,579
U01 · FY2014 · CA · contact PI
Development of anti-CXCR4 compounds to block breast cancer metastasis$341,139
R01 · FY2014 · CA · contact PI
Improving extent of glioblastoma resection by combining volumetric MRSI and 5-ALA$336,932
R21 · FY2014 · CA · contact PI
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$671,166
U01 · FY2013 · CA · contact PI
Development of anti-CXCR4 compounds to block breast cancer metastasis$330,588
R01 · FY2013 · CA · contact PI
Development of anti-CXCR4 compounds to block breast cancer metastasis$365,440
R01 · FY2012 · CA · contact PI
Development of PET Imaging Probes for Chemokine Receptors for Head....$144,676
P50 · FY2012 · CA · contact PI
Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma$327,011
R21 · FY2011 · CA · contact PI
Development of PET Imaging Probes for Chemokine Receptors for Head....$187,245
P50 · FY2011 · CA · contact PI
Blockade of the SDF-1/CXCR4 axis as a novel strategy for mitigating radiation-ind$850,335
RC1 · FY2010 · AI
Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma$337,125
R21 · FY2010 · CA · contact PI
Development of anti-CXCR4 compounds as anti-metastatic, angiogenic drug$263,700
R01 · FY2010 · CA · contact PI
Development of PET Imaging Probes for Chemokine Receptors for Head....$236,472
P50 · FY2010 · CA · contact PI
Inhibition of the SDF-1/CXCR4 axis as preventive therapy for radiation-induced pu$232,500
R21 · FY2010 · HL
Development of anti-CXCR4 compounds as anti-metastatic, angiogenic drug$263,700
R01 · FY2009 · CA · contact PI
Development of PET Imaging Probes for Chemokine Receptors for Head....$202,958
P50 · FY2009 · CA · contact PI
Inhibition of the SDF-1/CXCR4 axis as preventive therapy for radiation-induced pu$193,750
R21 · FY2009 · HL
Development of anti-CXCR4 compounds as anti-metastatic, angiogenic drug$263,700
R01 · FY2008 · CA · contact PI
Development of PET Imaging Probes for Chemokine Receptors for Head....$129,102
P50 · FY2008 · CA · contact PI
Development of anti-CXCR4 compounds as anti-metastatic, angiogenic drug$263,700
R01 · FY2007 · CA · contact PI
Res Proj 2: Development of PET Imaging Probes for Chemokine Receptors for Head...$52,823
P20 · FY2007 · CA · contact PI
Development of anti-CXCR4 compounds as anti-metastatic, angiogenic drug$271,575
R01 · FY2006 · CA · contact PI